GenMark Diagnostics Expands Role of Jon Faiz Kayyem, Ph.D. to Serve as Head of Research and Development

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that, effective immediately, Jon Faiz Kayyem, Ph.D., the Company’s Founder and Chief Scientific Officer, will serve as the Company’s Senior Vice President of Research and Development with overall responsibility for the Company’s research and development activities. Dr. Kayyem replaces Jorge Garces, who has resigned to pursue other opportunities.

GenMark’s President and CEO, Hany Massarany, commented, “As the Founder and former Chief Executive Officer of the Company and the inventor of our core eSensor® technology, Faiz is a natural fit to lead our research and development organization. Faiz’s scientific expertise, long and successful history with the Company, and comprehensive involvement on our XT-8 portfolio expansion and NexGen development project make him uniquely qualified to assume this role.”

Dr. Kayyem stated, “I am extremely excited about this opportunity and the excellent progress we have made developing our NexGen system and its related assay menu. With our results-driven team, our highly focused development, engineering and manufacturing partnerships and the recent addition of key R&D personnel, GenMark is well positioned to deliver on our product development commitments.”

Dr. Kayyem originally founded Clinical Micro Sensors (CMS) in 1995 to commercialize technical innovations he developed while at The California Institute of Technology. He remained with CMS until 2004, when he co-founded the biotechnology fund management company Efficacy Capital Limited. CMS was acquired by Osmetech plc in 2005. Dr. Kayyem rejoined the Company in January 2009, serving as Osmetech’s chairman of the board of directors from January 2009 to August 2009. From August 2009 through Osmetech’s reorganization as GenMark Diagnostics in February 2010, he served as the Company’s President and Chief Executive Officer. Dr. Kayyem continued as GenMark’s President and CEO following the reorganization until August 2010, when he assumed the position of Chief Scientific Officer with leadership responsibility for the Company’s research and development organization. Dr. Kayyem received a combined M.S. and B.S. in Molecular Biophysics and Biochemistry from Yale University and his Ph.D. in Molecular Biology from The California Institute of Technology.

ABOUT GENMARK

GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark’s proprietary eSensor® detection technology, GenMark’s eSensor® XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets four tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory Virus Panel, Thrombophilia Risk Test, and Warfarin Sensitivity Test. A number of other tests, including HCV Genotyping, 2C19 Genotyping, and 3A4/3A5 Genotyping are available for research use only. For more information, visit www.genmarkdx.com.

GenMark® and eSensor® and our other logos and trademarks are the property of GenMark Diagnostics, Inc. or its subsidiaries.

SAFE HARBOR STATEMENT

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our growth strategy, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, our research and development plans and timelines, including with respect to the expected completion of our NexGen system, inherent risk and uncertainty in the protection of our intellectual property rights, and regulatory uncertainties regarding approval or clearance for our products, as well as other risks and uncertainties described under the “Risk Factors” in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.